Portal de Periódicos da CAPES

Revisão Acesso aberto Produção Nacional Revisado por pares

BIBTEX RIS

Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group

2021; Elsevier BV; Volume: 22; Issue: 3 Linguagem: Inglês

10.1016/s1470-2045(20)30756-7

1474-5488

Philippe Moreau, Shaji Kumar, Jesús F. San Miguel, Faith E. Davies, Elena Zamagni, Nizar J. Bahlis, Heinz Ludwig, Joseph Mıkhael, Evangelos Terpos, Fredrik Schjesvold, Thomas G. Martin, Kwee Yong, Brian G.M. Durie, Thierry Façon, Artur Jurczyszyn, Surbhi Sidana, Noopur Raje, Niels W.C.J. van de Donk, Sagar Lonial, Michèle Cavo, Sigurður Y. Kristinsson, Suzanne Lentzsch, Roman Hájek, Kenneth C. Anderson, Cristina João, Hermann Einsele, Pieter Sonneveld, Monika Engelhardt, Rafaël Fonseca, Annette Juul Vangsted, Katja Weisel, Rachid Baz, Vânia Hungria, Jesús G. Berdeja, Fernando Leal da Costa, Ângelo Maiolino, Anders Waage, David H. Vesole, Enrique M. Ocio, Hang Quach, Christoph Driessen, Joan Bladé, Xavier Leleu, Eloísa Riva, P. Leif Bergsagel, Jian Hou, Wee Joo Chng, Ulf-Henrik Mellqvist, Dominik Dytfeld, Jean‐Luc Harousseau, Hartmut Goldschmidt, Jacob P. Laubach, Nikhil C. Munshi, Francesca Gay, Meral Beksaç, Luciano J. Costa, Martin Kaiser, Parameswaran Hari, Mario Boccadoro, Saad Z. Usmani, Sonja Zweegman, Sarah A. Holstein, Orhan Sezer, Simon J. Harrison, Hareth Nahi, Gordon Cook, María‐Victoria Mateos, S. Vincent Rajkumar, Meletios Α. Dimopoulos, Paul G. Richardson,

Ubiquitin and proteasome pathways

This Policy Review presents the International Myeloma Working Group's clinical practice recommendations for the treatment of relapsed and refractory multiple myeloma. Based on the results of phase 2 and phase 3 trials, these recommendations are proposed for the treatment of patients with relapsed and refractory disease who have received one previous line of therapy, and for patients with relapsed and refractory multiple myeloma who have received two or more previous lines of therapy. These recommendations integrate the issue of drug access in both low-income and middle-income countries and in high-income countries to help guide real-world practice and thus improve patient outcomes.